-+ 0.00%
-+ 0.00%
-+ 0.00%

Teva, Trump administration pursue Medicaid drug pricing agreement under GENEROUS framework

PUBT·08/31/2026 20:07:35
Listen to the news
Teva, Trump administration pursue Medicaid drug pricing agreement under GENEROUS framework
  • Teva began talks with the Trump Administration on an agreement to cut Medicaid prices for select medicines in the U.S.
  • Framework would align Medicaid pricing with leading developed markets through Teva’s GENEROUS model.
  • Prospective most-favored-nation commitment would apply to certain future innovative product launches.
  • Offer includes a dedicated reserve of certain active pharmaceutical ingredients to support public health needs.
  • Teva also proposed continued investment in U.S. pharmaceutical manufacturing capabilities; final terms remain confidential.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608311606OMX_____CNEWS_EN_GNW1001260271_en) on August 31, 2026, and is solely responsible for the information contained therein.